Organization | University of Health Sciences Lahore

University of Health Sciences Lahore Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2017

NCT04078048

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Shahbaz Ahmad | Shehnoor Azhar | the university of lahore | The University of Lahore | University of Health Sciences Lahore | University of Lahore

Active Ingredients

Drugs in Phase 3 Trials (6)

azithromycin (zithromax) (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

immune globulin (human) (1 trial)

oseltamivir (tamiflu) (1 trial)

vitamin c (2 trials)

vitamin e (1 trial)

Drugs in Phase 2 Trials (1)

caraway oil (1 trial)

Drugs in Other Trials (4)

magnesium (1 trial)

nitroglycerin (transderm-nitro) (1 trial)

potassium (1 trial)

tocilizumab (actemra) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Chronic Periodontitis (Phase 2)

Periodontitis (Phase 2)

Schizophrenia (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 28
# of Trial APIs: 11